Seqker - About the company
Seqker is an unfunded company, founded in 2021. It operates as a Developer of vaccines for the treatment of cancer. Seqker has not raised any funding yet. The company has 3299 active competitors, including 1118 funded and 778 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of vaccines for the treatment of cancer. The company focuses on genomic profiling for biomarker/target identification and neoantigen cancer vaccine treatments. The company's lead candidate is the SQK01 Neoantigen cancer vaccine.
Key Metrics
Founded Year
2021
Stage
Unfunded
Ranked
2403rd among 3299 active competitors
Employee Count
3 as on Jun 30, 2026
Similar Companies
Sign up to download Seqker's company profile
Seqker's funding and investors
Seqker has not raised any funding rounds yet.
Seqker's founders and board of directors
Founder? Claim ProfileSeqker's employee count trend
Seqker has 3 employees as of Jun 26. Here is Seqker's employee count trend over the years:
Uncover Seqker's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Seqker's Competitors and alternates
Top competitors of Seqker include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Seqker, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 80/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 73/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
2403rd |  Seqker 2021, Unfunded | Developer of vaccines for the treatment of cancer | - | - | 24/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Seqker's competitors? Click here to see the top ones
Seqker's Investments and acquisitions
Seqker has made no investments or acquisitions yet.
Reports related to Seqker
Here is the latest report on Seqker's sector:
Are you a Founder ?
FAQs about Seqker
Explore our recently published companies
- Career & Corporate Services of the University of St.Gallen - Switzerland based, 2003 founded, Unfunded company
- HB Designovations - Mumbai based, 2010 founded, Unfunded company
- Fathom Realty - Columbus based, Unfunded company
- Landmor Partners - 2019 founded, Unfunded company
- Zanoch - Colombo based, Unfunded company
- Prime Business Consultants - Unfunded company
